A Single-Center Quasi-Experimental Study to Evaluate the Impact of Utilizing Rapid Diagnostic Technology to Detect Methicillin-Resistant
Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a relevant pathogen for patients with pneumonia in the presence of certain risk factors. Empiric broad-spectrum antimicrobial therapy, including anti-MRSA therapy, is frequently initiated in patients hospitalized with pneumonia. The low yield of respiratory cultures makes antimicrobial de-escalation difficult, potentially leading to extended durations of anti-MRSA therapy and increasing risk for significant drug-related adverse effects. A polymerase chain reaction (PCR) test that was previously utilized for nasal MRSA screening was internally validated to identify the presence of MRSA in respiratory specimens within 2 hours of sample collection. The primary objective of this study was to determine the effect of this respiratory PCR test on duration of anti-MRSA therapy in nonintensive care unit (ICU) patients hospitalized with pneumonia.
Methods. Implementation of the PCR test in non-ICU units occurred December 1, 2017. During the post-intervention (INT) period (December 1, 2017 -March 31, 2018 , PCR results were evaluated daily by antimicrobial stewardship and decentralized staff pharmacists for therapy de-escalation opportunities, with recommendations communicated to prescribers. The pre-INT group (December 1, 2016-March 31, 2017) consisted of non-ICU patients hospitalized with pneumonia who received anti-MRSA therapy for at least 48 hours, or who qualified for anti-MRSA therapy per institutional guidelines.
Results. A total of 169 patients were evaluated; 109 in the post-INT group and 60 in the pre-INT group. Anti-MRSA therapy was administered to 74 patients (68%) in the post-INT group, compared with 56 patients (93%) in the pre-INT group. The median duration of anti-MRSA therapy post-INT was 23.5 hours, which was significantly shorter than the pre-INT duration of 55.5 hours (P < 0.0001). The post-INT group also had significantly less vancomycin-induced nephrotoxicity (P < 0.0383) and a shorter time to targeted therapy (P < 0.0001). No difference in 30-day all-cause mortality was observed (P < 0.1338).
Conclusion. Utilization of a PCR test to detect MRSA in respiratory specimens decreased duration of anti-MRSA therapy in non-ICU patients hospitalized with pneumonia.
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The Scope of Mycoplasma Pneumoniae
Results. A total of 3,621 RVPs were tested with 49 positive for MPP. In regard to age of patients, 27/49 (incidence 2.7%) positive for MPP were under 5 years old as compared with 22/49 (incidence 1%) between 5-18 years old. 75% of RVPs obtained were in patients under 5 years of age. Cough and fever were present for a mean of 8.3 and 7.6 days, respectively prior to RVP. Of the MPP positive patients, 21/49 patients (43%) were treated with scheduled although only 16 had a history of wheezing. Of the MPP positive patients, 38/48 patients had radiological findings of a pulmonary infiltrate (not perihilar) with 30/38 patients (79%) had bilateral infiltrates. Admission antimicrobial therapy was the following: 8 on no antibiotic, 21 on nonmacrolide, 11 macrolide and nonmacrolide, and 9 on macrolide therapy alone. Pediatric intensive care unit (PICU) admission occurred in 8 patients: 4 direct PICU admissions and 4 patients transferred from wards to PICU. All four PICU transfers had initially nonmacrolide therapy; 3 of 4 were under 5 years of age.
Conclusion. Over half of Pediatric MPP was diagnosed by rapid molecular diagnostics in patients under 5 years of age. Bilateral pulmonary infiltrates and new onset wheezing responsive to β agonists were commonly noted in patients who had MPP. A small subset of those younger patients required higher level of care after initial therapy with nonmacrolide therapy. While MPP has a lower incidence among younger children, the infection is not rare and can have a significant clinical impact. MPP should be considered in all patients, especially younger patients who are nonresponsive to treatment of community acquired pneumonia.
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